High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma

被引：17

作者：

Hoskins, JM

Gross, AS

Shenfield, GM

Rivory, LP ^{[1
]}

机构：

[1] Royal N Shore Hosp, Dept Clin Pharmacol, St Leonards, NSW 2065, Australia

[2] Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia

来源：

JOURNAL OF CHROMATOGRAPHY B | 2001年 / 754卷 / 02期

基金：

英国医学研究理事会;

关键词：

moclobemide;

D O I：

10.1016/S0378-4347(00)00625-3

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

A rapid and sensitive liquid chromatography-electrospray ionisation mass spectrometry (HPLC-ESI-MS) assay has been developed for the measurement of moclobemide and metabolites, Ro12-5637 and Ro12-8095, in human plasma. Sample preparation (0.5 ml plasma) involves solid-phase extraction using C-18 cartridges. A Nova-Pak phenyl column (Waters, 4 mum, 150X2 mm I.D.) was employed for analyte separation with a mixture of 0.2 M ammonium formate buffer, pH 3.57 and acetonitrile as the mobile phase. The within- and bstween-day precisions of the assay were <18% and the limit of quantification for all analytes was 0.01 <mu>g/ml. The total run-time was 6 min. The method described was used to measure moclobemide, Ro12-5637 and Ro12-8095 in human plasma following an oral 300 mg dose. (C) 2001 Elsevier Science B.V. All rights reserved.

引用

页码：319 / 326

页数：8

共 11 条

[1] MODELING THE MARKET UPTAKE OF NEW DRUGS FOLLOWING LISTING FOR SUBSIDY IN AUSTRALIA - A REPORT FROM THE DRUG-UTILIZATION-SUBCOMMITTEE OF THE AUSTRALIAN-PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE [J].